Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1088 - Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC)


20 Dec 2015


Poster presentation 2


Daniel Tan


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


D. Tan1, C. Lin2, D. Chin-Lun Huang3, H. Jung4, T. Bogenrieder5, K. Park6

Author affiliations

  • 1 Medical Oncology, National Cancer Center, 169610 - Singapore/SG
  • 2 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei/TW
  • 3 Oncology Department, Boehringer Ingelheim Taiwan Limited, Taipei/TW
  • 4 Oncology Department, Boehringer Ingelheim Korea, Seoul/KR
  • 5 Oncology Department, Boehringer Ingelheim RCV, Vienna/AT
  • 6 Division Of Hematology-oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR


Abstract 1088


In preclinical studies, insulin-like growth factor (IGF) signaling has been implicated in acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This trial evaluates BI 836845, an IGF ligand-neutralizing antibody that binds to both IGF-1 and IGF-2 and neutralizes growth-promoting signaling, combined with afatinib in patients (pts) with EGFR-mutated NSCLC.

Trial design

This open-label, dose-escalation trial in Korea, Taiwan and Singapore (NCT02191891; 1280.16) consists of a dose confirmation part (Part A) followed by an expansion part (Part B). Eligible pts are aged ≥18 years with advanced and/or metastatic NSCLC progressing during prior treatment with EGFR TKI or platinum-based chemotherapy (Part A) or prior EGFR TKIs (Part B), with a documented activating EGFR mutation and no EGFR T790M mutation (Part B only). Pts with prior afatinib therapy below assigned dose level (Part A only) or <30 mg/day (Parts A and B), or progressive disease (PD) on an insufficient dose of EGFR TKI prior to study in investigator's opinion, or >2 (Part B only) prior EGFR TKI regimens for relapsed/metastatic NSCLC are excluded. Part A uses a 3 + 3 design to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI 836845 plus afatinib (starting dose: BI 836845 1000 mg/week 1-hour intravenous infusion plus oral afatinib 30 mg/day in 4-week courses). Pts receive treatment until PD, intolerability or study discontinuation. In Part A, pts are entered sequentially into escalating/de-escalating dose tiers (3–6 pts/cohort) to determine the MTD based on dose-limiting toxicities (DLTs) during Course 1; 6 additional pts will be enrolled in an extension cohort at the RP2D. In Part B, two expansion cohorts of 18 pts previously treated with irreversible EGFR TKIs (e.g. afatinib, dacomitinib; Cohort 1) or reversible EGFR TKIs (gefitinib or erlotinib; Cohort 2) will receive the RP2D determined in Part A. Primary endpoints are MTD and DLTs during Course 1 (Part A) and objective response (OR; Part B). Secondary endpoints include disease control, time to OR, duration of OR, and pharmacokinetics. All analyses will be descriptive and exploratory.

Clinical trial identification

NCT02191891; Study 1280.16


D. Chin-Lun Huang, H. Jung, T. Bogenrieder: employment: Boehringer Ingelheim. HK. Park: Advisory board: Astellas, AZ, BI, Clovis, Eli Lilly, Hanmi, KHK, Novartis, ONO, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings